“Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study”, J of Skin, vol. 4, no. 5, p. s67, Sep. 2020, doi: 10.25251/skin.4.supp.66.